Abeona Therapeutics Inc. (ABEO) — Financial statements
Income statement, balance sheet, and cash flow for Abeona Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 6 | 0.00↓100.0% | 4↑147.5% | 1↓52.9% | 3 | |
| Cost of Revenue | 2↓47.3% | 3↑81.1% | 2↑256.7% | 0.45 | 0.00 | |
| Gross Profit | 4↑247.5% | -3↓253.4% | 2↑96.6% | 0.96↓67.9% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 27↓22.0% | 34↑10.5% | 31↑7.3% | 29↓25.2% | 39 | |
| General & Administrative Expenses | 65↑117.9% | 30↑57.1% | 19↑10.1% | 17↓20.3% | 22 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 65↑117.9% | 30↑57.1% | 19↑10.1% | 17↓20.3% | 22 | |
| Other Expenses | 2↑165.1% | -3↓173.0% | -1↓118.8% | 6↓82.6% | 32 | |
| Operating Expenses | 94↑52.9% | 61↑25.0% | 49↓5.5% | 52↓44.1% | 93 | |
| Total Costs & Expenses | 95↑48.4% | 64↑26.8% | 51↓3.2% | 52↓43.6% | 93 | |
| Operating Results | ||||||
| Operating Income | -89↓39.3% | -64↓36.2% | -47↑7.4% | -51↑43.3% | -90 | |
| Depreciation & Amortization | 4↑22.6% | 3↓9.1% | 3↓30.1% | 5↑2.5% | 4 | |
| EBITDA | -86↓51.7% | -57↓12.0% | -51↓47.1% | -34↑55.2% | -77 | |
| EBIT | -89↓50.3% | -60↓10.7% | -54↓38.0% | -39↑52.1% | -81 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑4678.9% | 0.04↓97.8% | 2↑657.0% | -0.31↑91.6% | -4 | |
| Interest Income | 6↑30.9% | 4↑100.6% | 2↑391.2% | 0.43↑977.5% | 0.04 | |
| Interest Expense | 4↓11.1% | 4↑906.7% | 0.42↓43.2% | 0.74↓79.9% | 4 | |
| Non-Operating Income | -164↓3410.6% | -5↓170.6% | 7↑155.5% | -12↓39.7% | -9 | |
| Other Income / Expenses | 161↑33596.2% | 0.48↑106.8% | -7↓162.9% | 11↑129.0% | 5 | |
| Income Before Tax | 71↑211.8% | -64↓17.6% | -54↓36.5% | -40↑53.3% | -85 | |
| Income Tax Expense | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 71↑211.7% | -64↓17.6% | -54↓36.5% | -40↑53.3% | -85 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 71↑211.7% | -64↓17.6% | -54↓36.5% | -40↑53.3% | -85 | |
| Bottom-Line Net Income | 67↑205.2% | -64↓17.6% | -54↓24.6% | -43↑48.8% | -85 | |
| EPS (Basic) | 1.34↑186.5% | -1.55↑38.7% | -2.53↑54.2% | -5.53↑74.3% | -21.50 | |
| EPS (Diluted) | 1.01↑165.2% | -1.55↑38.7% | -2.53↑54.2% | -5.53↑74.3% | -21.50 | |
| Weighted Average Shares | 53↑29.0% | 41↑92.0% | 21↑171.9% | 8↑99.6% | 4 | |
| Weighted Average Diluted Shares | 66↑61.1% | 41↑92.0% | 21↑171.9% | 8↑99.6% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.